PORTSMOUTH, N.H., Jan. 17,
2025 /PRNewswire/ -- Laborie Medical
Technologies Corp. (Laborie), a leader in diagnostic and
therapeutic medical technologies, has reached a significant
milestone with its Optilume® Drug-Coated Balloon (DCB).
The groundbreaking treatment for recurrent bulbar urethral
strictures has had its five-year follow-up data from the ROBUST I
study published in the Journal of Urology. This data
underscores the durability, safety, and efficacy of Optilume as a
minimally invasive option for patients.
The study evaluated 53 men with recurrent bulbar strictures,
concluding that 71.7% of patients did not need repeat intervention.
Additionally, the average International Prostate Symptom Score
(IPSS) improved from a mean of 25.2 at baseline to 7.2 at five
years (p<0.001). The maximum flow rate improved from 5.0 mL/s at
baseline to 19.9mL/s (P < .01), and average postvoid residual
was reduced from 141.4 mL to 59.5 mL (P < .01). Erectile
function was unaffected, and there were no serious
treatment-related adverse events.
"Optilume DCB is a transformative addition to the treatment
algorithm for stricture patients," said Dr. Allen F. Morey, M.D., FACS. "With the robust
5-year clinical data, we now see its ability to provide durable,
long-term relief. It remains an excellent option for elderly
patients or those with comorbidities who are suboptimal candidates
for open surgery and for enhancing outcomes in complex stricture
management."
The Optilume DCB combines mechanical dilation with the localized
delivery of paclitaxel, a drug that inhibits tissue regrowth,
directly to the urethral tissue. This dual-action approach limits
scar tissue formation, breaking the cycle of stricture recurrence.
It also provides a less invasive and faster recovery alternative to
urethroplasty.
The ROBUST I data strengthens the evidence base for Optilume,
complementing findings from randomized controlled trials such as
ROBUST III, demonstrating superior outcomes over the standard of
care for recurrent anterior urethral strictures.
For more information on Optilume and its role in transforming
the treatment of urethral stricture disease, visit
www.optilume.com.
About Laborie Medical Technologies
Headquartered in Portsmouth, New
Hampshire, Laborie is a global medical technology company
focused on Urology, Urogynecology, Gastroenterology, Obstetrics,
Gynecology & Neonatal Health. We manufacture and deliver
high-quality, high-impact diagnostic and therapeutic products that
help clinicians and hospitals preserve and restore patient dignity.
Clinicians and hospitals look to us as the market-leading experts
in our business segments, and we support our products with a
world-class clinical education & information program. Laborie
is a portfolio company of Patricia Industries. For more
information, visit www.laborie.com.
View original
content:https://www.prnewswire.com/news-releases/optilume-drug-coated-balloon-shows-long-term-efficacy-for-urethral-strictures-five-year-data-published-in-the-journal-of-urology-302354239.html
SOURCE Laborie Medical Technologies
